Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of SBRT followed by AK112 in advanced hepatocellular carcinoma after first-line targeted-immunotherapy failure
ChiCTR2400086691Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of ivonescimab, sponsored by Zhongshan Hospital, Fudan University. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
ivonescimab
Beyond the preview
Go deeper on ChiCTR2400086691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086691.